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CIC

:   cell-in-cell

KRAS

:   Kirsten rat sarcoma viral oncogene

c-Myc

:   cellular myc

E-cadherin

:   epithelial cadherin

P-cadherin

:   placental cadherin
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Human tumors are heterogeneous and highly dynamic tissues that evolve from benign to malignant status. Although much has been learned over the last several decades about the genetics of tumor initiation and progression, the cellular mechanisms underlying clonal selection and tumor evolution remain poorly understood. In many cases cancers evolve by a long-term, stepwise process involving stages of oligoclonality,[@cit0001] in which multiple intratumoral cell clones compete in order to expand and invade normal tissue. How intratumoral cell clones interact with each other and with adjacent normal tissue is not well understood.

"Cell competition" was first reported in 1975 in the *Minute* mutant of *Drosophila melanogaster*, in which cells of heterozygous ribosome gene dosage, which are viable and able to form normal tissues, were found to be progressively eliminated when confronted with wild-type cells in mosaic tissues.[@cit0002] Further investigation led to the finding that the individual cells within developing organs undergo competition that contributes to tissue homeostasis, as only the fittest cells are selected for survival. Cell competition also occurs in mammalian tissues and may contribute to cancer initiation or progression, as wild-type cells could suppress tumorigenic outgrowth or, conversely, oncogene-expressing cells could induce the death of neighboring wild-type cells and invade normal tissue. In *Drosophila* and mammalian tissues, cells expressing certain oncogenes, for example cellular *Myc* (*c-Myc*), are indeed recognized as "fitter" and eliminate adjacent wild-type cells.[@cit0003] In this way, cell competition could promote tumor initiation by inducing so-called "field oncogenesis," whereby cells with activated oncogenic signaling replace wild-type cells in a phenotypically silent manner.[@cit0005] It is conceivable that intratumoral cell clones could also compete against each other, which could influence tumor evolution. Our recent findings demonstrate that entosis, a process by which winner tumor cells engulf and kill loser cells and benefit from their death, is one mechanism whereby cells within heterogeneous tumor cell populations might compete.[@cit0006]

Cell-in-cell (CIC) refers to the morphology of one or more viable cells present inside other cells, a phenomenon that has been documented in human tumors for many decades. One process leading to CIC formation is when epithelial cells or tumor cells engulf and kill their live neighbors by entosis.[@cit0009] We recently examined CIC formation in a panel of human breast tumor cells and found that the majority of cancer cell lines failed to form CIC structures, which correlated with a lack of expression of the epithelial cell-cell adhesion proteins E-cadherin (epithelial cadherin) or P-cadherin (placental cadherin). Entotic cell engulfment is known to require E- or P-cadherins, which mediate the engulfment process. The enforced expression of E- or P-cadherin induced CIC formation, suggesting a causal role of the loss of expression of these proteins in entosis resistance of human tumor cells. Expression of E- or P-cadherin also inhibited anchorage-independent growth, during which a high rate of entosis was observed, suggesting that entosis-mediated CIC formation and cell killing is a potential tumor suppressive pathway.[@cit0010]

The idea that entosis might function as a mechanism of cell competition came from the observation that a number of tumor cells could consistently engulf normal or non-transformed epithelial cells when admixed.[@cit0006] Further investigation indicated that the identity of the winner, or engulfing, cells during entosis was actually genetically controlled. Tumor cells with certain oncogenic mutations such as *KRASV12* (Kirsten rat sarcoma viral oncogene homolog mutated glycine to valine at position 12), which has been implicated in *Drosophila* cell competition, could win over those with wild-type *KRAS* through entosis. This effect was mediated by Ras-related C3 botulinum toxin substrate 1 (RAC1)-dependent inhibition of Ras homolog gene family member A (RHOA) activity, which is a key regulator of cell stiffness through actomyosin contraction. Relative cell deformability was correlated with winner or loser cell identity during entosis, whereby the stiffer cells were usually internalized by their softer neighbors.[@cit0006] Thus, entosis allows cells harboring different genetic mutations to compete such that winner status is dictated by the relative physical properties of cells in a heterogeneous population. This mechanism of competition selects for cells with greater mechanical deformability, a cell property that is known to correlate with tumor progression and metastatic potential.[@cit0006]

Although entosis is now known to mediate a form of cell competition, a more detailed understanding of the effects of this kind of neighbor-induced cell death on tumor progression awaits further study. It is conceivable that entosis might have different effects on tumor progression depending on tumor stage ([**Fig. 1**](#f0001){ref-type="fig"}). For example, during the initiation of a primary tumor, entosis might participate in the spread of oncogene-expressing cells that replace cells from normal tissue by mediating the engulfment and death of surrounding wild-type cells. These early events would be predicted to be phenotypically silent. Once a tumor is formed, entosis might also mediate competition between different intratumoral cell clones, in which cells with mutations that reduce cell stiffness are predicted to dominate the tumor tissue at the expense of loser clones. Winner cells are also known to become polyploid by this mechanism[@cit0008] and to recover nutrients from the loser cells that they ingest,[@cit0007] suggesting that this form of competition could support tumor progression for winner clones by multiple mechanisms. Figure 1.Hypothetical functional implications of entosis in oncogenesis and tumor progression. Entosis could conceivably facilitate field oncogenesis by replacing normal cells with mutant cells (stage I), or promote clonal selection by allowing winner cells to outcompete loser tumor cells (stage II). Some tumors may eventually reach an entosis-low state in which the cell population has become more homogeneous or epithelial-to-mesenchymal transition has inhibited this form of engulfment (stage III).
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